Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab.
Rimini M, Loi E, Rizzato MD, Pressiani T, Vivaldi C, Gusmaroli E, Antonuzzo L, Martinelli E, Garajova I, Giordano G, Lucchetti J, Schirripa M, Cornara N, Rossari F, Vitiello F, Amadeo E, Persano M, Piva VM, Balsano R, Salani F, Pircher C, Cascinu S, Niger M, Fornaro L, Rimassa L, Lonardi S, Scartozzi M, Zavattari P, Casadei-Gardini A. Rimini M, et al. Among authors: niger m. Target Oncol. 2024 Mar;19(2):223-235. doi: 10.1007/s11523-024-01032-5. Epub 2024 Feb 12. Target Oncol. 2024. PMID: 38345693
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer.
Pietrantonio F, Aprile G, Rimassa L, Franco P, Lonardi S, Cremolini C, Biondani P, Sbicego EL, Pasqualetti F, Tomasello G, Niger M, Casagrande M, Ghidini M, Muni R, Montrone S, Bergamo F, Berenato R, Fontanella C, Bozzarelli S, Moretto R, Battaglin F, Di Bartolomeo M, de Braud F, Miceli R. Pietrantonio F, et al. Among authors: niger m. Radiother Oncol. 2015 Nov;117(2):315-21. doi: 10.1016/j.radonc.2015.08.023. Epub 2015 Sep 4. Radiother Oncol. 2015. PMID: 26347495
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.
Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, Pietrantonio F, Morano F, Antista M, Lonardi S, Fornaro L, Tamberi S, Giommoni E, Zaniboni A, Rimassa L, Tomasello G, Sava T, Spada M, Latiano T, Bittoni A, Bertolini A, Proserpio I, Bencardino KB, Graziano F, Beretta G, Galdy S, Ventriglia J, Scagnoli S, Spallanzani A, Longarini R, De Vita F. Di Bartolomeo M, et al. Among authors: niger m. Target Oncol. 2018 Apr;13(2):227-234. doi: 10.1007/s11523-018-0562-5. Target Oncol. 2018. PMID: 29582224
Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram.
Pietrantonio F, Barretta F, Fanotto V, Park SH, Morano F, Fucà G, Niger M, Prisciandaro M, Silvestris N, Bergamo F, Fornaro L, Bordonaro R, Rimassa L, Santini D, Tomasello G, Antonuzzo L, Noventa S, Avallone A, Leone F, Faloppi L, Di Donato S, de Braud F, Lee J, De Vita F, Di Bartolomeo M, Miceli R, Aprile G. Pietrantonio F, et al. Among authors: niger m. Oncology. 2018;95(6):344-352. doi: 10.1159/000491753. Epub 2018 Aug 21. Oncology. 2018. PMID: 30130791
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassineti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F. Di Bartolomeo M, et al. Among authors: niger m. BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3. BMC Cancer. 2019. PMID: 30922323 Free PMC article. Clinical Trial.
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Pietrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smiroldo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, Petrelli F, Longarini R, Cinieri S, Falcone A, Zagonel V, Di Bartolomeo M, de Braud F. Pietrantonio F, et al. Among authors: niger m. JAMA Oncol. 2019 Sep 1;5(9):1268-1275. doi: 10.1001/jamaoncol.2019.1467. JAMA Oncol. 2019. PMID: 31268481 Free PMC article.
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.
Raimondi A, Di Maio M, Morano F, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Sartore-Bianchi A, Tampellini M, Ritorto G, Murialdo R, Clavarezza M, Zaniboni A, Adamo V, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Bergamo F, Niger M, Antista M, Peverelli G, de Braud F, Di Bartolomeo M, Pietrantonio F. Raimondi A, et al. Among authors: niger m. Eur J Cancer. 2020 Aug;135:230-239. doi: 10.1016/j.ejca.2020.04.048. Epub 2020 Jul 2. Eur J Cancer. 2020. PMID: 32623288 Free article. Clinical Trial.
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F, Fucà G, Rossini D, Schmoll HJ, Bendell JC, Morano F, Antoniotti C, Corallo S, Borelli B, Raimondi A, Marmorino F, Niger M, Boccaccino A, Masi G, Lonardi S, Boni L, de Braud F, Di Bartolomeo M, Falcone A, Cremolini C. Pietrantonio F, et al. Among authors: niger m. Oncologist. 2021 Apr;26(4):302-309. doi: 10.1002/onco.13642. Epub 2021 Jan 2. Oncologist. 2021. PMID: 33336844 Free PMC article.
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study.
Raimondi A, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Amatu A, Tampellini M, Racca P, Murialdo R, Clavarezza M, Zaniboni A, Toscano G, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Niger M, Antista M, Ambrosini M, Pagani F, Prisciandaro M, Randon G, de Braud F, Di Bartolomeo M, Pietrantonio F, Morano F. Raimondi A, et al. Among authors: niger m. Support Care Cancer. 2021 Jul;29(7):3971-3980. doi: 10.1007/s00520-020-05972-2. Epub 2021 Jan 3. Support Care Cancer. 2021. PMID: 33392769 Clinical Trial.
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index.
Rovesti G, Leone F, Brandi G, Fornaro L, Scartozzi M, Niger M, Yoo C, Caputo F, Filippi R, Casagrande M, Silvestris N, Santini D, Faloppi L, Palloni A, Aglietta M, Vivaldi C, Cho H, Lai E, Fenocchio E, Nichetti F, Pella N, De Lorenzo S, Di Maio M, Vasile E, de Braud F, Jeong JH, Aprile G, Orsi G, Cascinu S, Casadei-Gardini A. Rovesti G, et al. Among authors: niger m. J Gastrointest Cancer. 2022 Jun;53(2):289-298. doi: 10.1007/s12029-021-00596-z. Epub 2021 Feb 5. J Gastrointest Cancer. 2022. PMID: 33544375
80 results